Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine

Journal of Medical Virology

Volumn 85, Issue 9, 2013, Pages 1591-1597

  Song, Joon Young ^a   Cheong, Hee Jin ^a   Noh, Ji Yun ^a   Seo, Yu Bin ^a   Choi, Won Suk ^a   Cho, Geum Joo ^b   Hwang, Taik Gun ^b   Kim, Woo Joo ^a  

^a Korea University College of Medicine   (South Korea)

^b Gurogu Public Health Center   (South Korea)

Author keywords

Elderly; Immunogenicity; Influenza vaccine; MF59 adjuvant

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE;

AGED; ANTIBODY TITER; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CROSS REACTION; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA B; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; SEROCONVERSION; SHORT COURSE THERAPY; VACCINATION;

ELDERLY; IMMUNOGENICITY; INFLUENZA VACCINE; MF59 ADJUVANT;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SQUALENE; VACCINATION; VACCINES, INACTIVATED;

EID: 84880357009     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23630     Document Type: Article

References (17)

1. Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, Icardi G. 2010. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 28:4123-4129.
2. Chun BC, Choi WS, Kim J, Jeong SY, Jang EJ, Lee HJ, Kim WJ, Cheong HJ. 2011. Estimation of mortality and morbidity attributable to influenza by influenza virus types and subtypes in Korea. The Fourth ESWI Influenza Conference. Malta. p B615P.
3. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A. 1999. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17:3094-3101.
4. Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A. 2006. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24:3063-3065.
5. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, Rappuoli R. 2011. Influenza vaccine immunology. Immunol Rev 239:167-177.
6. Durando P, Icardi G, Ansaldi F. 2010. MF59-adjuvanted vaccine: A safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 10:639-651.
7. European. 1997. Note for guidance on harmonisation of requirements for influenza vaccines. London, UK: The Europen Agency for the Evaluation of Medicinal Products.
8. Gaillat J, Dennetiere G, Raffin-Bru E, Valette M, Blanc MC. 2008. Summer influenza outbreak in a home for the elderly: Application of preventive measures. J Hosp Infect 70:272-277.
9. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A. 2001. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 17:135-140.
10. Hannoun C, Megas F, Piercy J. 2004. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103:133-138.
11. Kendal AP, Pereira MS, Skehel JJ. 1982. Concepts and procedures for laboratory based influenza surveillance. Geneva: Viral Disease Unit, World Health Organization.
12. Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, Xu H, Takashita E, Tashiro M, Takao S, Yano T, Suga T, Kawakami C, Yamamoto M, Kajiyama K, Saito H, Shimada S, Watanabe S, Aoki S, Taira K, Kon M, Lin JH, Odagiri T. 2012. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol 19:897-908.
13. Legrand J, Vergu E, Flahault A. 2006. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24:6605-6611.
14. McElhaney JE, Hooton JW, Hooton N, Bleackley RC. 2005. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 23:3294-3300.
15. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P. 1999. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17:99-104.
16. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186.
17. Xie H, Jing X, Li X, Lin Z, Plant E, Zoueva O, Yang H, Ye Z. 2011. Immunogenicity and cross-reactivity of 2009-2010 in activated seasonal influenza vaccine in US adults and elderly. PLoS ONE 6:e16650.